Guardant Health, Inc. , a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally.
Guardant Health stock last closed at $29.73, up 1.26% from the previous day, and has increased 31.37% in one year. It has overperformed other stocks in the Diagnostics & Research industry by 0.44 percentage points. Guardant Health stock is currently +88.05% from its 52-week low of $15.81, and -19.74% from its 52-week high of $37.04.
As of Nov 12, 2024, there are 123.55M shares of GH outstanding. The market capitalization of GH is $3.67B. In the past 24 hours, 1.92M GH shares were traded.
You will need a brokerage account to access the NASDAQ market and buy GH stock.
Based on our analysis, eToro is the best online stock brokerage. Here's why:
Get $10 towards your purchase of stock by signing up for an account with eToro today.
Open eToro AccountNow that you've picked your brokerage, you need to fill out some personal info so you are able to invest in GH stock today.
Now that you've finished signing up on the best stock trading app, you need to deposit funds:
Check out the video below for more details depositing funds into your investment account.
After you have decided on the best place to buy Guardant Health stock, it's absolutely critical to analyze their stock prior to buying, so you actually wrap your head around the risk and opportunity.
WallStreetZen was built to help everyday investors do better fundamental analysis.
You can see all of the due diligence checks on GH's stock page.
You can use many financial metrics, analyses, models, and charts to gauge GH's intrinsic value.
You can access additional valuation research on GH's stock here.
Out of 14 Equities analysts who research GH, the consensus analyst rating on Guardant Health is a Strong Buy
Please keep in mind that analyst ratings are not recommendations, nor are they financial advice.
David Westenberg, a top 10% analyst from Piper Sandler maintains GH with a strong buy rating and raises their GH price target from $30.00 to $34.00, on Aug 13, 2024.
Piper Sandler's David Westenberg raised their price target on Guardant Health (NASDAQ: GH) by 13.3% from $30 to $34 on 2024/08/13. The analyst maintained their Strong Buy rating on the stock.
Westenberg's price target hike and model update on Guardant Health were part of a post-print review of names in their Healthcare (Labs and Genomic Tools) sector coverage area.
Guardant Health reported its Q2 2024 earnings on 2024/08/07.
For Q2 20204, Guardant Health reported:
For FY 2024, management guided:
Co-founder & Co-CEO Helmy Eltoukhy commented: "We had another strong quarter driven by solid volume growth, particularly for biopharma, and continued improvements to Guardant360 reimbursement.
“We also reached major milestones across our oncology business with the upgrades of Guardant360 onto our Smart Liquid Biopsy platform, a revolutionary platform that combines genomics with epigenomics, and of Guardant360 TissueNext to identify more treatment options for patients with advanced cancer.
"Additionally, our COSMOS study was recently published in Clinical Cancer Research and submitted to MolDx for Medicare reimbursement of CRC surveillance.
"We look forward to continuing this momentum throughout the remainder of the year as we deliver on our mission of giving us all more time free from cancer.”
Co-Founder & Co-CEO AmirAli Talasaz added: "FDA approval of our Shield blood test for first-line colorectal cancer screening is a huge victory for Guardant and patients.
“Commercial launch of Shield and CMS coverage make our blood-based screening option accessible to more than 45M Medicare beneficiaries.
"Shield offers a more pleasant way to stay up to date with colorectal cancer screening and detect the disease early, when it is more easily treated.”
Patrick B Donnelly, a top 17% analyst from Citigroup maintains GH with a strong buy rating and raises their GH price target from $40.00 to $45.00, on Aug 8, 2024.
Dan Brennan, a top 16% analyst from TD Cowen maintains GH with a strong buy rating and raises their GH price target from $41.00 to $42.00, on Aug 8, 2024.
Alex Nowark, a top 34% analyst from Craig-Hallum maintains GH with a buy rating and raises their GH price target from $28.00 to $37.00, on Aug 8, 2024.
Mark Massaro, a top 28% analyst from BTIG maintains GH with a strong buy rating and raises their GH price target from $45.00 to $50.00, on Jul 30, 2024.
You can dive deeper into what analysts are forecasting on the Guardant Health stock forecast page.
Last year, GH revenue was $692.26M. In the past five year, GH's revenue has gone up by 30.29% per year. This was faster than the Diagnostics & Research industry average of 9.55%.
Find out more about GH's earnings and revenue performance here.
Over the past year, insiders at GH have bought more shares than they have sold.
Darya Chudova, Chief Technology Officer of GH, was the latest GH insider to sell. They sold $116,702.00 worth of GH stock on Nov 4, 2024.
Research more about who owns GH stock here.
No, Guardant Health doesn't provide an income stream by paying out dividends.
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other traders have to say.
There are two primary order types:
Press the Open button and your broker will place the order.
If you need additional help investing in stocks on eToro, watch the helpful video below:
Now that you own some GH shares, you'll want to stay up-to-date on your stock purchase.
Create a watchlist to track your GH stock.
To summarize, here are the 6 steps you need to take to buy Guardant Health stock right now:
If you require a place to buy stocks, eToro is our recommended option.
Get Started with eToro TodayIf you would like to get updates on your investment in Guardant Health, add GH to your watchlist by clicking the button below.